The global dupuytren’s disease market size was estimated at USD 4.13 billion in 2022 and is projected to reach USD 5.87 billion by 2030, growing at a compound annual growth rate (CAGR) of 4.55% from 2023 to 2030. The growth is primarily driven by the rising prevalence of the disease and continuous advancements in medical research and technology.
As the market evolves, it creates opportunities for stakeholders to develop innovative therapies that address patient needs and improve disease management outcomes. According to the Journal of Hand Surgery, the development of additional nonsurgical treatment approaches is crucial, as these can reduce the risks associated with invasive procedures and lower recurrence rates. This ongoing focus encourages discussions among hand surgeons and researchers about novel modalities that can benefit both patients and healthcare providers.
The market’s expansion is further supported by the rising number of diagnosed cases. A recent study published in the Journal of Hand Surgery highlighted a significant increase in incidence, indicating a growing patient population requiring effective management solutions. This has led to greater investments in research and development from pharmaceutical companies and medical device manufacturers. Furthermore, a 2021 U.S. population survey revealed that up to 7% of the population experiences clinical symptoms, with more than one-third of those affected reporting disruptions in daily activities due to Dupuytren’s contractures.
Key Market Highlights:
- Europe held the largest revenue share of 41.86% in 2022.
- By disease type, type II led the market in 2022 with a revenue share of 62.50%.
- By type, the treatment segment dominated in 2022 with a revenue share of 78.96%.
- By end-use, the hospital segment accounted for the largest share of 64.44% in 2022.
Download a free sample PDF of the Dupuytren’s Disease Market Intelligence Study from Grand View Research.
Market Performance:
- 2022 Market Size: USD 4.13 Billion
- 2030 Projected Market Size: USD 5.87 Billion
- CAGR (2023–2030): 4.55%
- Europe: Largest market in 2022
- Asia Pacific: Fastest-growing market
Prominent Companies & Market Dynamics:
The market growth is fueled by rising awareness, treatment innovations, and the expanding patient base, offering significant opportunities for major players to deliver advanced therapies and specialized care. Companies are actively pursuing strategies such as mergers, acquisitions, and collaborations to strengthen their market presence and meet growing demand.
For example, in April 2022, 180 Life Sciences and the University of Oxford announced positive results from a Phase 2b study for Dupuytren’s, marking a key milestone. Similarly, in April 2023, Ventoux Biosciences, a specialty pharmaceutical company focused on fibrotic diseases, was launched. The company has initiated pre-clinical evaluation of its pipeline candidates VEN-201 and VEN-202, aiming to deliver life-changing therapies for Dupuytren’s disease.
Key Companies:
- Bayer AG
- Novartis AG
- Pfizer Inc.
- Nantong Jinghua Pharmaceutical Co., Ltd.
- Actiza Pharmaceutical Private Limited
- Endo International plc
- Bristol-Meyers Squibb Company
- Spear Pharmaceuticals
- GSK plc
- AstraZeneca
- Hikma Pharmaceuticals PLC
- LEO Pharma A/S
- Fresenius Kabi AG
Explore Global Industry Herald for Insights that Drive Smarter Decisions
Conclusion
The dupuytren’s disease market is set for steady growth, supported by rising prevalence, technological advancements, and robust R&D activity. With an increasing focus on nonsurgical treatments and innovative therapies, stakeholders have the opportunity to enhance patient outcomes and shape the future of disease management.
No comments:
Post a Comment